An initial sum of $200 million has been received upfront, with the possibility of an additional $200 million in proceeds. This funding is anticipated to cover the costs associated with finalizing the Phase 3 ENSURE trials for relapsing multiple sclerosis, commencing the Phase 3 trial for primary progressive multiple sclerosis, and facilitating the transition into the next phase of the project.